# EyePoint, Inc.: overview EYPT · Nasdaq · CIK 1314102 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/eypt.md) · [Financials](/companies/eypt/financials.md) · [Filings](/companies/eypt/filings.md) · [Insiders](/companies/eypt/insiders.md) Latest reported revenue: [$507.0k](/filings/0001193125-26-335037.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-335037). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [10.5](/filings/0001193125-25-269471.md) | [11.6 d](/filings/0001193125-26-093917.md) | [24.5](/filings/0001193125-26-211870.md) | [5.3](/filings/0001193125-26-335037.md) | [1.0](/filings/0001193125-25-269471.md) | [0.6 d](/filings/0001193125-26-093917.md) | [0.7](/filings/0001193125-26-211870.md) | [0.5](/filings/0001193125-26-335037.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(311.2%)](/filings/0001193125-25-269471.md) | [(390.4%) d](/filings/0001193125-26-093917.md) | [(199.7%)](/filings/0001193125-26-211870.md) | [(1166.8%)](/filings/0001193125-26-335037.md) | [(6420.8%)](/filings/0001193125-25-269471.md) | [(11346.0%) d](/filings/0001193125-26-093917.md) | [(12532.5%)](/filings/0001193125-26-211870.md) | [(19207.1%)](/filings/0001193125-26-335037.md) | | Net margin | % | [(279.0%)](/filings/0001193125-25-269471.md) | [(357.3%) d](/filings/0001193125-26-093917.md) | [(184.8%)](/filings/0001193125-26-211870.md) | [(1114.3%)](/filings/0001193125-26-335037.md) | [(6183.4%)](/filings/0001193125-25-269471.md) | [(10904.7%) d](/filings/0001193125-26-093917.md) | [(12188.5%)](/filings/0001193125-26-211870.md) | [(18633.1%)](/filings/0001193125-26-335037.md) | | Diluted EPS | $ per share | [(0.54)](/filings/0001193125-25-269471.md) | not reported | [(0.65)](/filings/0001193125-26-211870.md) | [(0.85)](/filings/0001193125-26-335037.md) | [(0.85)](/filings/0001193125-25-269471.md) | not reported | [(0.99)](/filings/0001193125-26-211870.md) | [(1.09)](/filings/0001193125-26-335037.md) | | Free cash flow | $m | [(40.6) d](/filings/0001193125-25-269471.md) | [(36.2) d](/filings/0001193125-26-093917.md) | [(53.4)](/filings/0001193125-26-211870.md) | [(63.8) d](/filings/0001193125-26-335037.md) | [(60.2) d](/filings/0001193125-25-269471.md) | [(66.0) d](/filings/0001193125-26-093917.md) | [(81.5)](/filings/0001193125-26-211870.md) | [(63.5) d](/filings/0001193125-26-335037.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [36.9](/filings/0000950170-23-007180.md) | [41.4](/filings/0000950170-24-028523.md) | [46.0](/filings/0000950170-25-034601.md) | [43.3](/filings/0001193125-26-093917.md) | [31.4](/filings/0001193125-26-093917.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(149.6%)](/filings/0000950170-23-007180.md) | [(240.6%)](/filings/0000950170-24-028523.md) | [(163.1%)](/filings/0000950170-25-034601.md) | [(337.1%)](/filings/0001193125-26-093917.md) | [(776.0%)](/filings/0001193125-26-093917.md) | | Net margin | % | [(158.1%)](/filings/0000950170-23-007180.md) | [(247.0%)](/filings/0000950170-24-028523.md) | [(153.8%)](/filings/0000950170-25-034601.md) | [(302.4%)](/filings/0001193125-26-093917.md) | [(739.4%)](/filings/0001193125-26-093917.md) | | Diluted EPS | $ per share | [(2.03)](/filings/0000950170-23-007180.md) | [(2.74)](/filings/0000950170-24-028523.md) | [(1.82)](/filings/0000950170-25-034601.md) | [(2.32)](/filings/0001193125-26-093917.md) | [(3.17)](/filings/0001193125-26-093917.md) | | Free cash flow | $m | [(50.3)](/filings/0000950170-23-007180.md) | [(67.2)](/filings/0000950170-24-028523.md) | [(1.6)](/filings/0000950170-25-034601.md) | [(130)](/filings/0001193125-26-093917.md) | [(243)](/filings/0001193125-26-093917.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/eypt/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [MONTANOVA CAPITAL, LLC](/funds/1569064.md) | 2026-06-30 | $118.6m | 8,296,375 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $106.7m | 7,463,197 | | Added +285,860 | | [Cormorant Asset Management, LP](/funds/1583977.md) | 2026-06-30 | $100.1m | 7,000,000 | | Reduced −1,265,000 | | [FEDERATED HERMES, INC.](/funds/1056288.md) | 2026-06-30 | $81.2m | 5,681,052 | | Added +11,463 | | [ADAGE CAPITAL PARTNERS GP, L.L.C.](/funds/1165408.md) | 2026-06-30 | $69.0m | 4,827,792 | | Added +1,527,792 | | [FRANKLIN RESOURCES INC](/funds/38777.md) | 2026-06-30 | $68.7m | 4,807,078 | | Reduced −241,520 | | [Commodore Capital LP](/funds/1831942.md) | 2026-06-30 | $65.8m | 4,600,000 | | Added +1,775,000 | | [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $53.9m | 3,770,381 | | Not compared | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $51.9m | 3,630,252 | | Added +70,683 | | [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $46.4m | 3,601,168 | | Not compared | ## Recent filings [All 1,014 filings](/companies/eypt/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-19 | 09:22 ET | [8-K](/filings/0001193125-26-424755.md) | 2.02 Results of operations; 2.05 Exit or disposal costs; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-424755 | | 2026-10-19 | 07:05 ET | [8-K](/filings/0001193125-26-424644.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-424644 | | 2026-09-10 | 07:05 ET | [8-K](/filings/0001193125-26-387197.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-387197 | | 2026-08-17 | 08:50 ET | [8-K](/filings/0001193125-26-353308.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-353308 | | 2026-08-05 | 16:05 ET | [10-Q](/filings/0001193125-26-335037.md) | Quarterly report, period 2026-06-30 | 0001193125-26-335037 | | 2026-08-05 | 07:05 ET | [8-K](/filings/0001193125-26-333821.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-333821 | | 2026-07-30 | 07:05 ET | [8-K](/filings/0001193125-26-324866.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-324866 | | 2026-07-17 | 16:05 ET | [8-K](/filings/0001193125-26-307792.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-307792 | | 2026-06-22 | 07:05 ET | [8-K](/filings/0001193125-26-276688.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-276688 | | 2026-05-14 | 07:05 ET | [8-K](/filings/0001193125-26-222750.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-222750 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-093917.md), filed Mar 5, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1314102 - Tickers: EYPT - Exchange: Nasdaq - SIC code: 3826 Laboratory Analytical Instruments - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 11:47 ET. No prices; not investment advice.